Scarica l'app Stockscreener
31.20
4.73%
-1.55
Dopo l'orario di chiusura:
31.13
-0.07
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$32.75
Aprire:
$32.5
Volume 24 ore:
6.30M
Relative Volume:
0.60
Capitalizzazione di mercato:
$12.19B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.5739
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-7.69%
1M Prestazione:
+24.75%
6M Prestazione:
+13.29%
1 anno Prestazione:
-22.83%
Intervallo 1D:
$31.07
$32.66
Intervallo di 1 settimana:
$31.07
$35.90
Portata 52W:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
31.20 | 12.80B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday - ts2.tech
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - The Newark Advocate
Forget Moderna Stock, This is a Much Better Buy - Yahoo Finance
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts - ts2.tech
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday? - Benzinga
Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts - MSN
Moderna: On Transition From Pandemic Windfall To Multi-Product Platform, Initiating At Neutral - Seeking Alpha
Massachusetts lands rare manufacturing wins from Moderna and Alnylam amid tariff push - The Business Journals
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Pueblo Chieftain
Corient Private Wealth LLC Has $1.54 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Biotech Stocks To Keep An Eye OnDecember 24th - MarketBeat
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets - ts2.tech
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna: Why I Am Selling The 'Relief Rally' (NASDAQ:MRNA) - Seeking Alpha
Moderna Stock (MRNA) Drops on Dec. 23, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Moderna (NASDAQ:MRNA) Trading Down 5.8%Here's Why - MarketBeat
Moderna price drops — what’s behind today’s move (December 23) - Traders Union
Moderna CEO Bancel holds expiring stock options, bets on drugmaker's recovery - The Business Journals
Thrivent Financial for Lutherans Has $2.57 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Fayetteville Observer
Moderna up almost 4%, looking to continue outperformance streak - TradingView — Track All Markets
COVID-19 Vaccine Market set for steady growth to US$ 29.98 - openPR.com
Moderna’s Strategic Moves Aim to Fortify Its Financial Future - AD HOC NEWS
Rivian, Sandisk, And Moderna Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?Affirm Holdings (NASDAQ:AFRM), BioMarin Pharmaceutical (NASDAQ:BMRN), Carnival (NYSE:CCL), Lumentum Holdi - Benzinga
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Daytona Beach News-Journal
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine - Daily Commercial
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025) - ts2.tech
Moderna to Host Investor Event – Analyst Day - The Holland Sentinel
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Enterprise News
Ideas Watch: How buybacks impact Moderna Inc. stock valueJuly 2025 Levels & Daily Momentum Trading Reports - Улправда
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab - Finviz
CEPI to fund Moderna’s mRNA pandemic flu candidate - The Pharma Letter
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Down 80%, Should You Buy the Dip on Moderna? - Finviz
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):